Thanks -- yes, you are right, he did say that in the 27 May webinar. Not sure what that does to the timeline but his 7 Oct comments may reflect either a change in position regarding timing or substantial progress in arranging one or more new phase 2 trials. I can't see them bedding down new phase 2 protocols in other indications until they have reached agreement with FDA on PMS Phase 3.
NEU Price at posting:
$11.01 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)